Browse Studies — Arctuva

Phase 2

A Phase 2 Posology Study With Long-Term Extension in Participants With Well-Controlled Recurrent Pericarditis to Evaluate the Efficacy and Safety of Transition Regimens to KPL-387 Monotherapy From Standard Therapies

The primary objective of this study is to characterize the efficacy and safety of dosing regimens used to transition from prior pericarditis therapies to KPL-3…

Recurrent PericarditisHeart DiseasesPericarditis

Estimated

~$10 – $8,750

Kiniksa Pharmaceuticals International, plcNCT07288216

Phase 2

A Phase 2a, Open-Label Pilot Study to Evaluate the Safety/Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VTX2735 in Participants With Recurrent Pericarditis

This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP). Cohort A will include approx…

Recurrent Pericarditis

Estimated

~$10 – $8,750

Zomagen Biosciences Ltd.NCT06836232

Phase 3

CardiolRxTM in Recurrent Pericarditis (MAVERIC Phase 3) A Randomized, Double-blind, Placebo-controlled Trial

Multi-center, randomized, double-blind, placebo-controlled, phase-3 Trial. Patients with a history of recurrent pericarditis who are being treated with an IL-1…

Recurrent Pericarditis

Estimated

~$10 – $8,750

Cardiol Therapeutics Inc.NCT06708299

Phase 2

A Phase 2/3 Efficacy and Safety Study of KPL-387 Treatment in Participants With Recurrent Pericarditis

This study is being done to demonstrate whether KPL-387 is an effective and safe treatment for recurrent pericarditis.

PericarditisPericarditis AcuteRecurrent Pericarditis

Estimated

~$10 – $8,750

Kiniksa Pharmaceuticals International, plcNCT07010159